SCHEMBL1821181

SCHEMBL1821181

[NH]C(=O)CCCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5841454 0.94 LMNA (0.69)
SCHEMBL5841186 0.91 TSHR (0.71)
SCHEMBL9034003 0.91 TSHR (0.71)
Glutarate SCHEMBL8618878 0.87 SLC22A6 (0.92)
Glutarate SCHEMBL27601182 0.83 SLC22A6 (1.00)
Glutarate SCHEMBL158774 0.83 SLC22A6 (1.00)
Glutarate SCHEMBL6701735 0.83
Glutarate SCHEMBL7414 0.83
SCHEMBL1498152 0.80
Glutarate SCHEMBL104915 0.79 SLC22A6 (0.92)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US claimed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP claimed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US claimed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP claimed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US claimed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO claimed
EP-0469919-B1 A process for the enzymatic preparation of 7-aminocephalosporanic acid ANTIBIOTICOS SPA (IT) 1997-04-09 EP claimed
US-5354667-A Use of recombinant DNA techniques ANTIBIOTICOS, S.P.A. (IT) 1994-10-11 US claimed
EP-0469919-A2 A process for the enzymatic preparation of 7-aminocephalosporanic acid ANTIBIOTICOS, S.p.A. (IT) 1992-02-05 EP claimed
US-3976546-A HYDROLYSIS, ESTERASE GLAXO LABORATORIES LIMITED (EN) 1976-08-24 US claimed
JP-52128295-A None JP disclosed
JP-63074488-A None JP disclosed
US-9587129-B2 Ink composition and ink set SEIKO EPSON CORPORATION (JP) 2017-03-07 US disclosed
US-20160137859-A1 INK COMPOSITION AND INK SET SEIKO EPSON CORPORATION (JP) 2016-05-19 US disclosed
US-20160032125-A1 INK SET SEIKO EPSON CORPORATION (JP) 2016-02-04 US disclosed
US-4242449-A 7-Methoxy cephalosporins and process of producing them YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1980-12-30 US disclosed
US-4164447-A TRANSFERS A CARBAMOYL GROUP TO 3-HYDROXYMETHYL CEPHALOSPORIN GLAXO LABORATORIES LIMITED (GB) 1979-08-14 US disclosed
US-4144391-A REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE ELI LILLY AND COMPANY (US) 1979-03-13 US disclosed
JP-S52128295-A PREPARATION OF CEPHALOSPORINS TOYO JOZO CO LTD 1977-10-27 JP disclosed
US-3976546-A HYDROLYSIS, ESTERASE GLAXO LABORATORIES LIMITED (EN) 1976-08-24 US disclosed